MorphoSys AG

MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
  • Ticker663200
  • ISINDE0006632003
  • SectorPharmaceuticals & Biotechnology
  • CountryGermany

Analysts

Gary Waanders

MORPHOSYS: Tafasitamab (MOR208): L-MIND Q&A call follow-up | BUY | EUR120(+28%)

MORPHOSYS - BUY | EUR120(+28%) Tafasitamab (MOR208): L-MIND Q&A call follow-up Q&A call: slightly more detail on final analysis of L-MIND Differences in key measures from those reported at ASH Dec 2018 Competitive position relative to CAR-T in r/r DLBCL TAF outlook

Gary Waanders

MORPHOSYS: Tafasitamab (MOR208): L-MIND Q&A call follow-up | BUY | EUR120(+28%)

MORPHOSYS - BUY | EUR120(+28%) Tafasitamab (MOR208): L-MIND Q&A call follow-up Q&A call: slightly more detail on final analysis of L-MIND Differences in key measures from those reported at ASH Dec 2018 Competitive position relative to CAR-T in r/r DLBCL TAF outlook

Gary Waanders

MORPHOSYS: Tafasitamab (MOR208): L-MIND primary endpoint met | BUY | EUR120(+28%)

MORPHOSYS - BUY | EUR120(+28%) Tafasitamab (MOR208): L-MIND primary endpoint met Primary analysis confirms previously published activity Key L-MIND results BLA filing on-track by end 2019 2019 outlook

Gary Waanders

MORPHOSYS: MorphoSys Q1: holding course | BUY | EUR120(+35%)

MORPHOSYS - BUY | EUR120(+35%) MorphoSys Q1: holding course MorphoSys holding a steady course MOR208 (tafasitamab) rolling NDA filing progressing Key pipeline continuing to advance Positive outlook for 2019

Thomas J. Schiessle

MOR 208 Produktfamilie wird breiter – frequenter Newsflow absehbar

Die Entwicklungs- zum vollintegrierten Pharma-Unternehmen - mit der Produktfamilie MOR208 im Zentrum – nimmt Fahrt auf. Die Guidance19 scheint uns (wie bereits in der Vergangenheit) konservativ abgefasst zu sein.  Der angestrebte Launch von MOR208 in den USA ab H2/20e scheint durchfinanziert; die Landesorganisation wird jetzt aufgebaut. Die Entwicklungspipeline (115 Partner-Projekte - davon 29 in der Klinik) wird zunehmend breiter und reifer. 

Gary Waanders

MORPHOSYS: With strong 2018, MOR in excellent shape for 2019 | BUY | EUR120(

MORPHOSYS - BUY | EUR120(+39%) With strong 2018, MOR in excellent shape for 2019 2018 financial summary 2018 operational progress 2019 calendar looks busy for news flow Financial outlook for 2019

1 director sold

A director at Morphosys Ag sold 8,927 shares at 93.918EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Henning Steinbrink ...
  • Roland Pfaender,MBA,CFA,CCRA

Software AG : H1 2018 update of our ODDO BHF small/mid-cap Germany Conviction List

>Updating our Conviction List on German small-and mid-caps - We are updating our Conviction List for German small-and mid-cap companies selected from the ODDO BHF coverage universe. We believe companies on this list, selected on the basis of bottom-up, valuation and momentum considerations, have the potential to outperform their respective indices over an investment horizon of up to 12 months. We will continue to actively review our Conviction List, adding or remov...

Increased risk weighs on MORPHOSYS AG, penalising its rating down to Slightly Negative

The independent financial analyst theScreener just lowered the general evaluation of MORPHOSYS AG (DE), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Slightly Negative. As of the analysis date March 12, 2019, the closing price was EUR 86.35 and its target price was estimated at EUR 75.49.

Expert Corporate Governance Service (ECGS)

MorphoSys - AGM 22 May 2019

General: MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. It's Partnered Discovery segment business applies the Company's proprietary technologies to the research, development and optimisation of therapeutic antibody drug candidates in partnerschips with pharmaceutical and biotechnology companies. In the second segment, Proprietary Development, MorphoSys develops innovative proprietary antibody products. MorphoSys's scientists concentrate on indications such as inflammatory and autoimmune diseases, as well as cancer and infectious diseases. A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch